Merck recalls MMR vaccine after missed checks; FDA accepts HEPLISAV for review;

> Merck has recalled a batch of measles, mumps, and rubella vaccine that was shipped before final checks; however, its quality, safety, and effectiveness have been confirmed. Article

> Merck is the subject of a lawsuit alleging fraud over the efficacy of mumps vaccines; this has the potential to play into the hands of the anti-vaccine lobby groups. Article

> The FDA has accepted for review Dynavax Technologies' BLA for HEPLISAV, its vaccine against hepatitis B. Press release

> Australian vaccine company BioDiem has licensed hepatitis B and D vaccine technology from the University of Canberra. Press release

> DNA vaccine generates anti-nicotine antibodies to treat nicotine addiction. Press release | Article

> University of Maryland researchers are developing a vaccine against Salmonella based around a microbe that envelops itself in salt. Article

> The Australian Flumum study will look at the protection that vaccinating women for flu will give to their babies in the first year of life. Article

> Indonesia is producing 50,000 units of bird flu vaccine. Article

> The DoH in the Philippines is adding rotavirus vaccine to the national program. Article

> Soligenix has announced a collaboration with the Infectious Disease Research Institute to develop heat-stable biodefense vaccines. Press release

> DPT vaccine production has started again in India after failure to comply with GMP codes. Article

> Walgreen is offering whopping cough vaccines across Kansas. Press release

And Finally… A new vaccine fridge can keep shots cool for 4 days in a power outage. Press release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.